Pliant Therapeutics(PLRX) - 2023 Q4 - Annual Results

Exhibit 99.1 Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results Positive interim 12-week safety and ef icacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC • Positive safety and efficacy data from 320 mg dose cohort of INTEGRIS-PSC Phase 2a trial in patients with primary sclerosing cholangitis (PSC). At a once-daily dose of 320 mg, bexotegrast was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events. ...